Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.

Marco Metra Matteo Pagnesi Brian Lee ClaggettRafael DíazG Michael Felker John Joseph Valentine McMurray Scott D Solomon Diana Bonderman James C Fang Cândida Fonseca Eva Goncalvesova Jonathan G Howlett Jing LiEileen O'MearaZi Michael Miao Siddique A Abbasi Stephen B Heitner Stuart Kupfer Fady I Malik John R Teerlink

Published in: European heart journal (2022)

In GALACTIC-HF, risk reduction of heart failure outcomes with omecamtiv mecarbil compared with placebo was large and significant in patients with low SBP. Omecamtiv mecarbil did not affect SBP and was well tolerated independent of SBP values.

Keyphrases

heart failure
acute heart failure
blood pressure
phase iii
left ventricular
cardiac resynchronization therapy
clinical trial
study protocol
atrial fibrillation
heart rate
hypertensive patients
phase ii
double blind
placebo controlled
glycemic control
insulin resistance